Project Grant R00HL169903
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
- Virginia Commonwealth University was awarded a $210,611.86 Project Grant from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute on January 31, 2021. The grant supports research under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate "Tissue Stiffness Promotes Pro-Fibrotic Metabolic Dysregulation in Lung Fibrosis." This two-year project aims to foster basic research on the relationship between tissue...
- This federal Project Grant award of $644,997.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify proteomic biomarkers that can predict the progression of idiopathic pulmonary fibrosis (IPF), a severe and often fatal lung disease. The research aims to develop non-invasive assessments that can identify individuals at higher risk of developing IPF and those with more progressive forms of the disease, enabling earlier...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This federal Project Grant award for $806,901.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of oxidation-specific IgA antibodies in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The research, conducted by the University of Virginia, aims to elucidate the link between B cells, IgA, and lung fibrosis in IPF, with the goal of providing insight into disease mechanisms and identifying...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The $728,577 grant, awarded to the Regents of the University of California, San Francisco, aims to investigate the mechanisms by which the ATP receptor P2RX4 influences fibrotic pathways in lung fibroblasts. The research seeks to elucidate the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
- This federal Project Grant award of $159,624.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Vanderbilt University Medical Center (VUMC) to investigate the role of hypoxia-inducible factor (HIF) in promoting alveolar regeneration and functional lung repair for patients with idiopathic pulmonary fibrosis (IPF) and other chronic lung diseases. The research aims to explore how modulating upstream disease mechanisms,...